Outcome of Board meeting held on 3rd April 2024 is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.6 pts more than Nifty Microcap 250 and 5.5 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Indrayani Biotech approved an amendment to its earlier Rights Issue plan, changing the instrument from fully paid-up equity shares to partly paid-up equity shares of Rs.10 face value, for an amount not exceeding Rs.49.90 Crores. A Rights Issue Committee has been formed to finalise terms such as issue price, entitlement ratio, and record date. Separately, CFO Vinayaka Bodala resigned citing personal reasons, effective April 3, 2025, and Dhinakaran Rajagopal (formerly Chief Coordination Officer with 34 years of experience, including stints at Infosys, BHEL, and Indian Oil) was appointed as the new CFO on the same date. The trading window remains closed until 48 hours after Q4FY25 results are declared.
Shareholders may need to arrange funds for a partly paid-up rights issue of up to Rs.49.90 Crores, with the final record date and pricing yet to be announced — this could be dilutive depending on the issue price. The CFO change appears routine and well-managed with an internal elevation, likely not material to the stock.